U.S. Markets close in 4 hrs 9 mins
  • S&P 500

    4,639.40
    +72.40 (+1.59%)
     
  • Dow 30

    34,869.89
    +386.17 (+1.12%)
     
  • Nasdaq

    15,762.29
    +224.60 (+1.45%)
     
  • Russell 2000

    2,247.54
    +48.63 (+2.21%)
     
  • Crude Oil

    68.08
    +1.90 (+2.87%)
     
  • Gold

    1,787.60
    +11.10 (+0.62%)
     
  • Silver

    22.52
    -0.30 (-1.29%)
     
  • EUR/USD

    1.1324
    -0.0015 (-0.1359%)
     
  • 10-Yr Bond

    1.4750
    +0.0320 (+2.22%)
     
  • Vix

    22.69
    -4.50 (-16.55%)
     
  • GBP/USD

    1.3310
    +0.0008 (+0.0626%)
     
  • USD/JPY

    112.8720
    -0.3080 (-0.2721%)
     
  • BTC-USD

    58,624.57
    +1,540.24 (+2.70%)
     
  • CMC Crypto 200

    1,493.62
    +24.54 (+1.67%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

What Type Of Shareholders Make Up Guardant Health, Inc.'s (NASDAQ:GH) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Guardant Health, Inc. (NASDAQ:GH) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

With a market capitalization of US$13b, Guardant Health is rather large. We'd expect to see institutional investors on the register. Companies of this size are usually well known to retail investors, too. In the chart below, we can see that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about Guardant Health.

Check out our latest analysis for Guardant Health

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Guardant Health?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Guardant Health. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Guardant Health's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. We note that hedge funds don't have a meaningful investment in Guardant Health. Our data shows that SoftBank Investment Advisers (UK) Limited is the largest shareholder with 7.0% of shares outstanding. In comparison, the second and third largest shareholders hold about 6.5% and 5.9% of the stock. Furthermore, CEO Helmy Eltoukhy is the owner of 3.5% of the company's shares.

A closer look at our ownership figures suggests that the top 14 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Guardant Health

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Shareholders would probably be interested to learn that insiders own shares in Guardant Health, Inc.. The insiders have a meaningful stake worth US$936m. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

With a 14% ownership, the general public have some degree of sway over Guardant Health. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With a stake of 7.0%, private equity firms could influence the Guardant Health board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Guardant Health better, we need to consider many other factors. Take risks for example - Guardant Health has 2 warning signs we think you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.